Acumen Pharmaceuticals (ABOS) vs BioCardia (BCDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioCardia (BCDA) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 42.7% versus a loss of 88.1%. Over five years, BCDA leads with a -97.6% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $11.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | BCDA |
|---|---|---|
| Share price | $0.1865 | $0.785 |
| Market cap | $13.49M | $11.88M |
| 1-day change | -3.52% | +1.60% |
| YTD return | -91.16% | -37.20% |
| 1-year return | -88.12% | -42.70% |
| 5-year return | -97.74% | -97.62% |
| EPS (TTM) | $-1.55 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-121.33M | $-8.23M |
| 52-week high | $3.60 | $1.80 |
| 52-week low | $0.16 | $0.66 |
| Distance from 52-week high | -94.82% | -56.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +3975.07% | +1874.52% |
| Average volume | 2.73M | 206.64K |
| Shares outstanding | 72.33M | 15.14M |
| Employees | 60 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed ABOS by 45.4 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
ABOS vs BCDA FAQ
Which is bigger, Acumen Pharmaceuticals or BioCardia?
Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $11.88M for BioCardia (BCDA).
Which stock has performed better over the past year, ABOS or BCDA?
BCDA returned -42.70% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and BioCardia in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.